Pharvaris reports Phase 2 CHAPTER-1 extension data showing long-term safety, attack-rate drop for deucrictibant in HAE
PHVS•Phase 3 and Phase 2 data on oral deucrictibant
Pharvaris outlined new Phase 3 and Phase 2 data for oral deucrictibant at the Bradykinin Symposium on Sept. 3-4, 2026.
- Phase 3 RAPIDe-3 analyses showed faster patient-reported improvement and earlier stabilization of hereditary angioedema attacks versus placebo.
- Phase 2 CHAPTER-1 open-label extension results indicated sustained attack prevention with long-term dosing, with favorable tolerability over extended follow-up.
- An integrated clinical review reported no meaningful cardiovascular safety concerns across the deucrictibant program.
